匹多莫德联合孟鲁司特钠治疗儿童支气管哮喘的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 匹多莫德联合孟鲁司特钠治疗儿童支气管哮喘的临床观察
TITLE:
摘要: 目的:观察匹多莫德联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效及安全性。方法:选取支气管哮喘患儿120例,按随机数字表法分为对照组和观察组,各60例。两组患儿均给予雾化吸入糖皮质激素和积极抗感染等常规治疗。对照组患儿在常规治疗的基础上睡前口服孟鲁司特钠咀嚼片5 mg,qd;观察组患者在对照组基础上口服匹多莫德胶囊0.4 g,qd。两组患儿均持续治疗3个月。观察两组患儿临床疗效及治疗前后血清白细胞介素4(IL-4)、干扰素γ(IFN-γ)、免疫球蛋白E(IgE)水平、T淋巴细胞亚群及肺功能指标,并比较两组患儿不良反应发生情况。 结果:观察组患儿临床有效率为88.3%,显著高于对照组的61.7%。两组患儿治疗前IL-4、IFN-γ、IgE水平、T淋巴细胞亚群、肺功能指标比较,差异无统计学意义(P>0.05),两组患者治疗后IL-4、IFN-γ、IgE水平、CD4+、CD4+/CD8+、肺功能指标均显著改善,且观察组明显优于对照组,差异均有统计学意义(P<0.05)。两组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论:匹多莫德联合孟鲁司特钠治疗儿童支气管哮喘疗效显著,能明显减轻患儿气道炎症,增强免疫能力,提高肺功能,且安全性较好。
ABSTRACT: OBJECTIVE: To observe clinical efficacy and safety of pidotimod combined with montelukast sodium in the treatment of children with bronchial asthma. METHODS: 120 children with bronchial asthma were randomly divided into control group and observation group, with 60 cases in each group. Both group were given routine treatment as aerosol inhalation of glucocorticoid and anti-infective treatment. Control group was additionally given Montelukast sodium chewable tablet 5 mg orally, qd, at bedtime; observation group was additionally given Pidotimod capsule 0.4 g,qd, on the basis of control group. Both group received treatment for consecutive 3 months. Clinical efficacies of 2 groups were observed as well as IL-4, IFN-γ, IgE, T lymphocyte subset and lung function indexes of 2 groups before and after treatment. The occurrence of ADR were compared between 2 groups. RESULTS: The effective rate of observation group was 88.3%, which was significantly higher than that of control group (61.7%). There was no statistical significance in IL-4, IFN-γ, IgE, T lymphocyte subset and lung function indexes between 2 groups before treatment (P>0.05). After treatment, IL-4, IFN-γ, IgE, CD4+, CD4+/CD8+ and lung function of 2 groups were improved significantly, and the observation group was significantly better than the control group, with statistical significance (P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS: Pidotimod combined with montelukast sodium is effective for children with bronchial asthma, and can significantly relieve airway inflammation, enhance immunity and improve lung function with good safety.
期刊: 2016年第27卷第29期
作者: 雷春霞,王石
AUTHORS: LEI Chunxia,WANG Shi
关键字: 匹多莫德;孟鲁司特钠;儿童;支气管哮喘
KEYWORDS: Pidotimod; Montelukast sodium; Children; Bronahial asthma
阅读数: 226 次
本月下载数: 4 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!